Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
Completed · Not applicable
Conditions studied: Kidney Transplantation, Chronic Allograft Nephropathy
In brief
The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment. There have been improvements for patients receiving kidney transplants, yet acute rejection is still a problem. This can lead to kidney failure over time. Patients whose graft fails to function properly in the first week after transplant do not do as well after 5 years as compared to patients without early problems. This study will see if Thymoglobulin, a drug that suppresses the immune system, will improve early graft function.
Key facts
- Study ID
- NCT00007787
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 350
- Starts
- 2000-04-01
- Expected to finish
- 2004-03-01
- Last updated by the study team
- 2013-01-23
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients may be eligible for this study if they:
- Are receiving a first or second kidney transplant.
- Are at least 21 years old.
- Understand the purposes and risks of the study and have given consent.
- Agree to use an acceptable form of birth control for a year following transplant.
You may not qualify if…
- Patients will not be eligible for this study if they:
- Have received a kidney transplant from a living donor.
- Have had multiple organ transplants.
- Are allergic to Thymoglobulin (contains a rabbit protein).
- Are pregnant.
Where it is running
- Ilene Blechman-Krom — Rockville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.